Literature DB >> 18952199

Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists.

Brennan M R Spiegel1, Wayne Ho, Eric Esrailian, Stephan Targan, Peter D R Higgins, Corey A Siegel, Marla Dubinsky, Gil Y Melmed.   

Abstract

BACKGROUND & AIMS: Despite the development of consensus guidelines in ulcerative colitis (UC), there remain several areas of uncertainty in the everyday management of this incompletely understood disease. We performed a national vignette survey to measure variations in decision-making in areas of controversy.
METHODS: We constructed a survey with 3 vignettes to measure decision-making in 4 areas of controversy in UC: (1) dysplasia management, (2) mesalamine dosing, (3) diagnostic testing for underlying Crohn's disease, and (4) treatment of steroid-refractory inpatient UC. We compared responses between a group of community gastroenterologists and UC experts.
RESULTS: We received 192 responses (36% response). Compared with community gastroenterologists, UC experts were more likely to endorse colectomy for both unifocal and multifocal low-grade dysplasia, use narrow band imaging and chromoendoscopy for surveillance colonoscopy, use high-dose mesalamine for inducing remission, use long-term mesalamine for cancer chemoprevention, order computed tomography enterography to evaluate for Crohn's disease, and to have a lower threshold to call for surgery consultation in steroid-refractory UC. There was little agreement regarding the optimal frequency of surveillance colonoscopy, even among experts. Most respondents favored using infliximab over cyclosporine in steroid-refractory UC.
CONCLUSIONS: Community gastroenterologists and UC experts vary dramatically in their approach to many areas of uncertainty in UC. The only area of consensus between groups is the use of infliximab over cyclosporine in steroid-refractory UC, itself a controversial decision. These data suggest that current practice patterns are highly disparate and focus attention on specific areas of disconnect that should be further investigated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18952199      PMCID: PMC3804428          DOI: 10.1016/j.cgh.2008.08.029

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  28 in total

1.  Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease.

Authors:  J A Eaden; J F Mayberry
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

2.  Guidelines for the management of inflammatory bowel disease in adults.

Authors:  M J Carter; A J Lobo; S P L Travis
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

3.  Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2004-07       Impact factor: 10.864

Review 4.  Quality of life of patients with ulcerative colitis: past, present, and future.

Authors:  E Jan Irvine
Journal:  Inflamm Bowel Dis       Date:  2008-04       Impact factor: 5.325

Review 5.  Defining and measuring quality of care: a perspective from US researchers.

Authors:  R H Brook; E A McGlynn; P G Shekelle
Journal:  Int J Qual Health Care       Date:  2000-08       Impact factor: 2.038

Review 6.  Instruments for quality of life assessment in patients with inflammatory bowel disease.

Authors:  A G Pallis; I A Mouzas
Journal:  Dig Liver Dis       Date:  2000-11       Impact factor: 4.088

Review 7.  Impact of inflammatory bowel disease on health-related quality of life.

Authors:  F Casellas; J López-Vivancos; M Vergara; J Malagelada
Journal:  Dig Dis       Date:  1999       Impact factor: 2.404

8.  Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.

Authors:  Gert Van Assche; Geert D'Haens; Maja Noman; Séverine Vermeire; Martin Hiele; Katrien Asnong; Joris Arts; Andre D'Hoore; Freddy Penninckx; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

Review 9.  Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Authors:  L Sutherland; J K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2003

10.  Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence.

Authors:  Sidney Winawer; Robert Fletcher; Douglas Rex; John Bond; Randall Burt; Joseph Ferrucci; Theodore Ganiats; Theodore Levin; Steven Woolf; David Johnson; Lynne Kirk; Scott Litin; Clifford Simmang
Journal:  Gastroenterology       Date:  2003-02       Impact factor: 22.682

View more
  19 in total

1.  Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.

Authors:  Javier P Gisbert; María Chaparro; Fernando Gomollón
Journal:  World J Gastroenterol       Date:  2011-08-14       Impact factor: 5.742

Review 2.  Quality of care delivered to hospitalized inflammatory bowel disease patients.

Authors:  Adam V Weizman; Geoffrey C Nguyen
Journal:  World J Gastroenterol       Date:  2013-10-14       Impact factor: 5.742

Review 3.  Quality Improvement Initiatives in Inflammatory Bowel Disease.

Authors:  Sameer K Berry; Corey A Siegel; Gil Y Melmed
Journal:  Curr Gastroenterol Rep       Date:  2017-08

Review 4.  Implementing quality measures for inflammatory bowel disease.

Authors:  Shahzad Ahmed; Corey A Siegel; Gil Y Melmed
Journal:  Curr Gastroenterol Rep       Date:  2015-04

Review 5.  The future developments in inflammatory bowel disease care.

Authors:  Peter Irving
Journal:  Frontline Gastroenterol       Date:  2012-05-31

6.  Guideline recommendations for treatment of patients with inflammatory bowel diseases are not implemented in clinical practice-results of a non-representative survey.

Authors:  Lea I Kredel; Oliver Schneidereit; Jörg C Hoffmann; Britta Siegmund; Jan C Preiß
Journal:  Int J Colorectal Dis       Date:  2018-12-07       Impact factor: 2.571

7.  Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts.

Authors:  Brennan M R Spiegel; Mary Farid; Eric Esrailian; Jennifer Talley; Lin Chang
Journal:  Am J Gastroenterol       Date:  2010-03-02       Impact factor: 10.864

8.  Variation in Care of Inflammatory Bowel Diseases Patients in Crohn's and Colitis Foundation of America Partners: Role of Gastroenterologist Practice Setting in Disease Outcomes and Quality Process Measures.

Authors:  Kimberly N Weaver; Michael D Kappelman; Robert S Sandler; Christopher F Martin; Wenli Chen; Kristen Anton; Millie D Long
Journal:  Inflamm Bowel Dis       Date:  2016-11       Impact factor: 5.325

9.  Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates.

Authors:  Joel H Rubenstein; Akbar K Waljee; Joanne M Jeter; Fernando S Velayos; Uri Ladabaum; Peter D R Higgins
Journal:  Am J Gastroenterol       Date:  2009-06-02       Impact factor: 10.864

10.  Timing of surgery in ulcerative colitis in the biologic therapy era-the patient's perspective.

Authors:  Jörn Gröne; Eva-Maria Lorenz; Claudia Seifarth; Hendrik Seeliger; Martin E Kreis; Mario H Mueller
Journal:  Int J Colorectal Dis       Date:  2018-07-12       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.